A Pilot Study to Assess the Feasibility and Acceptability of Newborn Screening Using in Silico Panel-based Solo Genome Sequencing in France

RecruitingOBSERVATIONAL
Enrollment

5,000

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2031

Conditions
Newborn Screening Programmes for Rare Diseases
Interventions
GENETIC

pGS-NBS

Collection of a second DBS card if the parents accept the pGS-NBS for their newborn

OTHER

Satisfaction questionnaire

questionnaire on information process of parents informed about pGS-NBS

OTHER

interview with HSS researcher

interview with a member of the HSS team on reasons for declining /accepting pGS-NBS

OTHER

satisfaction questionnaire

questionnaire on results delivery in parents having accepted the pGS-NBS

OTHER

Qualitative and quantitative longitudinal exploration

validated anxiety and depression scales to assess the psychosocial impact and perceived utility for 90 families whose child screened negative among which 30 families will be interviewed. Interviews and validated anxiety and depression scales will be suggested to all families receiving positive screening results

OTHER

Medical follow up

follow-up of true positives and false negatives based on medical records (vital status, care pathways) until 5 years after results delivery

Trial Locations (5)

21000

RECRUITING

CHU Dijon Bourgogne, Dijon

25000

NOT_YET_RECRUITING

CHU Besançon, Besançon

35203

NOT_YET_RECRUITING

CHU Rennes - Hôpital Sud, Rennes

44093

NOT_YET_RECRUITING

CHU Hôtel Dieu, Nantes

49933

NOT_YET_RECRUITING

CHU d'Angers, Angers

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER